Protective effect of fluvastatin on degradation of apolipoprotein B by a radical reaction in human plasma.

  title={Protective effect of fluvastatin on degradation of apolipoprotein B by a radical reaction in human plasma.},
  author={Sho Aoki and K. Ikeda and Mayumi Yamamura and Shosuke Kojo},
  journal={Biological \& pharmaceutical bulletin},
  volume={24 2},
Fluvastatin, which is a synthetic 3-hydroxy-3-methylglutaryl coenzyme (HMG-CoA) reductase inhibitor, its metabolites (M2, M3 and M4) and trolox all inhibited the decrease of apolipoprotein B-100 (apoB) and alpha-tocopherol in a radical reaction of human plasma initiated by Cu2+. The concentrations of fluvastatin, M2, M3, M4 and trolox for 50% inhibition (IC50) of apoB fragmentation were 405, 8.55, 1.75, 305, and 43.4 microM, respectively. The IC50 value of pravastatin, which is another HMG-CoA… Expand
Fluvastatin ameliorates the hyperhomocysteinemia-induced endothelial dysfunction: the antioxidative properties of fluvastatin.
It is hypothesized that the administration of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin, which is experimentally demonstrated to have antioxidative properties as one of its pleiotropic effects, is a useful strategy for eliminating the detrimental events induced by hyperhomocysteinemia. Expand
Potentially new isobaric metabolite of fluvastatin observed by LC-MS/MS during incurred sample analysis.
The investigation performed suggests that the interference is produced in vivo and is a possible metabolite of fluvastatin, which required chromatographic separation from fluVastatin to obtain a reliable bioanalytical method. Expand
Modulation of impact of high fat diet in pathological and physiological left ventricular cardiac hypertrophy by fluvastatin.
Fluvastatin, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, significantly attenuated PAAC induced left ventricular cardiachypertrophy and MABP whereas no significant change was observed in CST-induced cardiac hypertrophy. Expand


In vitro inhibitory effects of the optical isomers and metabolites of fluvastatin on copper ion-induced LDL oxidation.
It is concluded that not only 3R,5S-enantiomer of fluvastatin but also its optical counterpart and the metabolites also have a potential to show the anti-atherosclerotic effect through their antioxidative activities on lipid peroxidation. Expand
Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro.
It is concluded that the antioxidative effect of fluvastatin sodium is not a common property of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, but may be derived from its unique chemical structure. Expand
Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits.
The results suggest the direct antioxidative effect of fluvastatin on LDL oxidation in vivo may reduce the risk of this condition not only by lowering plasma cholesterol but also by protecting LDL from oxidation. Expand
[Antioxidative effects of fluvastatin, and its major metabolites [II]].
The results indicated that the antioxidative effects of (+)-FV were comparable to those of (-)-FVs, although the HMG-CoA reductase inhibitory activity of (+-FV was 30-fold higher than that of (-'-FV. Expand
Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
Because HMG-CoA reductase inhibitors can inhibit platelet aggregation, macrophage foam cell formation, and LDL oxidation, major contributors to atherogenesis, the use of these drugs can significantly attenuate the atherosclerotic process. Expand
Inhibitory effects of fluvastatin, a new HMG‐CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol‐fed rabbits
The decrease in vascular ACE activity by fluvastatin as well as the lipid‐lowering effect may reduce the risk of atherosclerosis progression in the vasculature. Expand
Facile degradation of apolipoprotein B by radical reactions and the presence of cleaved proteins in serum.
The results suggest that apoB is highly reactive toward radicals in vitro and in vivo, with reaction resulting in the cleavage of peptide bonds. Expand
Biotransformation of fluvastatin sodium in humans.
The metabolic pathways of fluvastatin sodium (FV; Lescol, Sandoz compound XU 62-320), [R*,S*-(E)]-(+-)-sodium-3,5-dihydroxy-7-[3- (4-fluorophenyl)-1-(1-methylethyl)-1H-indole-2-yl]-hept-6-enoate, aExpand
Fluvastatin: a review of its use in lipid disorders.
Three large randomised, double-blind trials show fluvastatin can help prevent CHD events or death and slow disease progression in patients with CHD with or without hypercholesterolaemia. Expand
Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Fluvastatin is effective and well tolerated in patients with hypercholesterolaemia and appears to have an economic advantage over other HMG-CoA reductase inhibitors, primarily as a result of its relatively low acquisition costs. Expand